International Perspectives in Individualizing Therapy Beyond Second-line Treatment for Colorectal Cancer
Source: International Perspectives in Individualizing Therapy Beyond Second-line Treatment for Colorectal Cancer

Module

In this case-based activity, gain evidence-based insights from international experts on therapeutic strategies for progressive metastatic colorectal cancer, from optimal sequencing of targeted agents to effective management of treatment-emergent adverse events.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan optimal, personalized treatment strategies for patients with metastatic CRC who have experienced failure of at least 2 lines of therapy
  • Develop preventive and emergent strategies to limit or resolve potential adverse events associated with newer agents used in the treatment of metastatic CRC
  • Communicate with patients to help them make informed decisions and actively participate in their care

Topics covered include:

  • Introduction
  • Case 1: Middle-Aged Patient Desiring Aggressive Treatment for Progressive RAS-Mutant Metastatic CRC
  • Case 2: Hand–Foot Skin Reaction in a Patient Receiving Regorafenib
  • Case 3: Febrile Neutropenia in a Patient Receiving TAS-102
  • Case 4: Patient With Progressive Metastatic MSI-High CRC
  • Case 5: Younger Patient With Worsening BRAF-Mutated Metastatic CRC
  • Concluding Remarks
 

Program Directors

  • Tanios Bekaii-Saab
    MD, FACP

Faculty

  • Khalid Alsaleh
    MD, FRCPC
    Svetlana I. Kutukova
    MD, PhD
    Suayib Yalcin
    MD
  • Release Date:
    March 08, 2018

Information on this Educational Activity

Program Directors

Tanios Bekaii-Saab, MD, FACP

Professor
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from Amgen and Merck.

 

Faculty

Khalid Alsaleh, MD, FRCPC


Associate Professor of Oncology
Oncology Center
King Saud University
Riyadh, Saudi Arabia

Khalid Alsaleh, MD, FRCPC, has disclosed that he has received consulting fees from Amgen, Bayer, and Roche.
 

Svetlana I. Kutukova, MD, PhD


Senior Lecturer
Department of Medical Oncology
Pavlov State Medical University
Medical Oncologist
Department of Chemotherapy
City Clinical Oncology Dispensary
St Petersburg, Russian Federation

Svetlana I. Kutukova, MD, PhD, has disclosed that she has received funds for research support from AstraZeneca, Merck, and Pierre-Fabre.
 

Suayib Yalcin, MD


Professor
Department of Medical Oncology
Hacettepe University Institute of Cancer
Ankara, Turkey

Suayib Yalcin, MD, has no real or apparent conflicts of interest to report.
 

Staff

Krista Marcello, 


Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.
 

Kristen M. Rosenthal, PhD


Senior Managing Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.
 

Megan Cartwright, PhD


Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.